Leanbio
Heidi Tveit is an accomplished professional with extensive experience in various leadership roles within the biotechnology and pharmaceutical sectors. Currently serving as a General Member on the Board of multiple organizations, including Leanbio Pro, GAT Biosciences, AdvanSyn Bio SL, GAT Therapeutics, ALGAKTIV, and Greenaltech since March 2021, Tveit also holds the position of CEO at Sana Pharma Medical OY, Sana Pharma Medical AB, and Sana Pharma Medical AS, contributing to the rapid growth of these companies across Scandinavia. Tveit has a robust educational background, with a Dr. scient. in Cell and Molecular Biology and advanced degrees in Biochemistry from the University of Oslo, complemented by board management training from BI Norwegian Business School. Additionally, Tveit has experience as Business Development Manager and CFO at Ørn forlag, a company focused on book publishing and production of GPS points of interest.
This person is not in any teams
This person is not in any offices
Leanbio
Leanbio is a market oriented CDMO that develops and manufactures biopharmaceutical products as New biological entities and Biosimilars, applying “Lean bioproduction” through tailored quality by design and ICH compliant approach in order to maximize project success, minimize time to market, costs and risks. Leanbio follows a knowledge-based strategy, applying cutting edge technological platforms and working altogether with customers through the different stages of development across project lifecycle: Platform development Specific development Process characterization Scale-up Manufacture Leanbio covers full value chain of services in the development and manufacture of biotherapeutics from gene to vial.